A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Refametinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 10 Jun 2017 Biomarkers information updated
- 15 Apr 2015 According to a Bayer HealthCare media release, data from this study presented at the American Association for Cancer Research (AACR) 106th Annual Meeting.
- 29 Oct 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.